Browse by Title

Type here to filter the list

D
Decoding complex drug-drug-renal disease interaction mediated by hepatic enzymes and transporters using PBPK approach
Favorite

Jin Dong, PhD – AstraZeneca ### 2360675###Chair###Associate Director###AstraZeneca###
Chair: Jin Dong, PhD – AstraZeneca
###
Decoding the Past, Crafting the Future: Unraveling the Role of Confounding in Exposure-Response Relationships for Small and Large Molecules
Favorite

David C. Turner, PhD – Genentech ### 2360707###Chair###Distinguished Scientist, Clinical Pharmacology###Genentech###
Chair: David C. Turner, PhD – Genentech
### @@@ Mitch Phelps, PhD (he/him/his) – The Ohio State University ### 2360708###Speaker###Professor, College of Pharmacy###The Ohio State University###
Speaker: Mitch Phelps, PhD (he/him/his) – The Ohio State University
### he/him/his @@@ Yulia Vugmeyster, PhD – Mural Oncology ### 2360706###Chair and Speaker###Executive Director, Clinical Pharmacology###Mural Oncology###
Chair and Speaker: Yulia Vugmeyster, PhD – Mural Oncology
### @@@ Youwei Bi, PhD – FDA, MD ### 2489375###Speaker###Team Lead###FDA, MD###
Speaker: Youwei Bi, PhD – FDA, MD
### @@@ Da Zhang ### 2514036###Speaker#########
Speaker: Da Zhang
###
Deep Learning in PKPD and Pharmacometrics: Diversity of Approaches and Applications
Favorite

Sean Hayes, PhD – Merck Research Laboratories ### 2360751###Chair and Speaker###Associate Director, Data Science###Merck Research Laboratories###
Chair and Speaker: Sean Hayes, PhD – Merck Research Laboratories
### @@@ Omid Bazgir, PhD (he/him/his) – Genentech Inc. ### 2360752###Speaker###Senior AI Scientist, Clinical Pharmacology M&S###Genentech Inc.###
Speaker: Omid Bazgir, PhD (he/him/his) – Genentech Inc.
### he/him/his @@@ Louis Joslyn, PhD – Preclinical and Translational Pharmacokinetics/Pharmacodynamics, Genentech ### 2453718###Speaker###Principal Scientist###Preclinical and Translational Pharmacokinetics/Pharmacodynamics, Genentech###
Speaker: Louis Joslyn, PhD – Preclinical and Translational Pharmacokinetics/Pharmacodynamics, Genentech
###
Designing evolution-based treatment strategies based on the principles of convexity and concavity
Favorite

Jeffrey West, PhD – H. Lee Moffitt Cancer Center & Research Institute ### 2408931###Speaker###Assistant Member###H. Lee Moffitt Cancer Center & Research Institute###
Speaker: Jeffrey West, PhD – H. Lee Moffitt Cancer Center & Research Institute
###
Development of a Quantitative Systems Pharmacology Model to Support the Clinical Development of T cell Redirecting Bi- and Tri-specific Antibodies for Patients with Relapsed/Refractory Multiple Myeloma
Favorite

Jin Niu, PhD (she/her/hers) – J&J ### 2360735###Speaker###Senior Scientist###J&J###
Speaker: Jin Niu, PhD (she/her/hers) – J&J
### she/her/hers
Development of A User-Friendly Platform for Model-Integrated Bioequivalence Analysis
Favorite

Andrew C. Hooker, PhD, ISOP member – Uppsala University ### 2360680###Speaker###Professor of Pharmacometrics###Uppsala University###
Speaker: Andrew C. Hooker, PhD, ISOP member – Uppsala University
###
Diversity and management of differences. Group-decision making and the role of psychological safety in effective decision making
Favorite

ENOCH COBBINA (he/him/his) – Syndax Pharmaceuticals ### 2360749###Speaker###Director###Syndax Pharmaceuticals###
Speaker: ENOCH COBBINA (he/him/his) – Syndax Pharmaceuticals
### he/him/his
Does the Why Lead to the How to Build Virtual Populations?
Favorite

Richard Allen, PhD – Pfizer ### 2360668###Speaker###Research Fellow and Quantitative Systems Pharmacology Lead###Pfizer###
Speaker: Richard Allen, PhD – Pfizer
###
Dose guidance for a novel combination therapy to treat head and neck squamous cell carcinoma (HNSCC) for patients with HRAS/PIK3CA variants using QSP model
Favorite

Amitava Mitra, PhD – Clinical Pharmacology ### 2360683###Speaker###Executive DIrector###Clinical Pharmacology###
Speaker: Amitava Mitra, PhD – Clinical Pharmacology
###
Dose Optimization of ADCs
Favorite

Rudy Gunawan, PhD – Pfizer ### 2360702###Speaker###Director, Pharmacometrics & System Pharmacology###Pfizer###
Speaker: Rudy Gunawan, PhD – Pfizer
###
Dose Selection and Optimization in Oncology: Focus on ADCs
Favorite

Tushar Garimella, PhD, ISoP member, ACCP member (he/him/his) – Daiichi Sankyo Inc ### 2360681###Speaker###Executive Director, Quantitative Clinical Pharmacology###Daiichi Sankyo Inc###
Speaker: Tushar Garimella, PhD, ISoP member, ACCP member (he/him/his) – Daiichi Sankyo Inc
### he/him/his
Drug combinations paired with strategic scheduling: leveraging quantitative systems pharmacology to overcome drug resistance
Favorite

Birgit Schoeberl, PhD – Novartis ### 2360742###Speaker###Global Head of Translational Modeling & Simulation and Data Science###Novartis###
Speaker: Birgit Schoeberl, PhD – Novartis
###